Nuvalent's shares surged 20% in premarket trading after positive updates on its cancer drug programs. Phase 1 trials showed promising results for zidesamtinib and NVL-655, with Phase 2 trials progressing well and pivotal data expected next year.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing